Table 3.
Associations between DRRD, ISD and ERDP mutually adjusted and overall mortality by subgroups of BC survivors.
| HR (95%CI) | ||||
|---|---|---|---|---|
| N cases (events) | DRRDa | ISDa | ERDPa | |
| All breast cancer survivors | 13,270 (2340) | 0.92 (0.87–0.96) | 1.06 (1.00–1.12) | 0.97 (0.92–1.03) |
| Menopausal status at diagnosis | ||||
| Premenopausal | 3070 (527) | 0.97 (0.87–1.07) | 0.95 (0.83–1.08) | 0.94 (0.83–1.06) |
| Postmenopausal | 10,200 (1813) | 0.91 (0.86–0.95) | 1.09 (1.02–1.16) | 0.99 (0.93–1.05) |
| P-value for heterogeneityb | 0.951 | 0.074 | 0.693 | |
| BMI | ||||
| Normal-weight | 7612 (1193) | 0.91 (0.85–0.97) | 1.10 (1.01–1.20) | 1.04 (0.96–1.12) |
| Overweight- obesity | 5452 (1113) | 0.93 (0.87–1.00) | 1.03 (0.95–1.12) | 0.93 (0.86–1.01) |
| P-value for heterogeneityb | 0.950 | 0.773 | 0.104 | |
| Physical activity level | ||||
| Inactive | 7393 (1468) | 0.90 (0.85–0.96) | 1.07 (0.99– 1.16) | 1.00 (0.93–1.07) |
| Active | 5682 (837) | 0.94 (0.87–1.01) | 1.02 (0.92–1.12) | 0.93 (0.85–1.02) |
| P-value for heterogeneityb | 0.716 | 0.970 | 0.464 | |
| Stage of tumour | ||||
| Metastatic (stage IV) | 1777 (585) | 0.89 (0.81–0.99) | 1.17 (1.04–1.33) | 1.02 (0.91–1.14) |
| Non-metastatic | 7834 (968) | 0.95 (0.88–1.02) | 1.02 (0.93–1.12) | 0.99 (0.91–1.08) |
| P-value for heterogeneityb | 0.261 | 0.795 | 0.089 | |
| Non-metastatic tumours | ||||
| Stage Ic | 1940 (108) | 0.93 (0.74–1.18) | 1.13 (0.85–1.50) | 1.14 (0.87–1.50) |
| Stage II | 1593 (250) | 0.95 (0.81–1.12) | 0.99 (0.82–1.20) | 0.90 (0.76–1.07) |
| Stage III | 303 (79) | 1.17 (0.84–1.63) | 0.82 (0.56–1.19) | 0.93 (0.65–1.34) |
| P-value for heterogeneityb | 0.269 | 0.716 | 0.131 | |
| Oestrogen receptor status | ||||
| ER(+) | 7500 (1071) | 0.91 (0.85–0.97) | 1.04 (0.95–1.13) | 1.01 (0.93–1.09) |
| ER(–) | 1678 (426) | 0.93 (0.84–1.05) | 1.17 (1.01–1.34) | 1.04 (0.91–1.19) |
| P-value for heterogeneityb | 0.764 | 0.402 | 0.244 | |
| Progesterone receptor status | ||||
| PR(+) | 5072 (620) | 0.88 (0.80–0.96) | 1.14 (1.02–1.29) | 0.98 (0.88–1.09) |
| PR(-) | 2612 (515) | 0.92 (0.83–1.03) | 1.08 (0.95–1.24) | 1.07 (0.95–1.20) |
| P-value for heterogeneityb | 0.819 | 0.169 | 0.980 | |
| HER2 status | ||||
| HER2(+) | 856 (166) | 1.07 (0.87–1.31) | 0.99 (0.78–1.25) | 1.09 (0.86–1.36) |
| HER2(–) | 3587 (473) | 0.88 (0.79–0.98) | 1.12 (0.98– 1.28) | 0.99 (0.87–1.12) |
| P-value for heterogeneityb | 0.956 | 0.631 | 0.934 | |
All models were stratified by country and menopausal status at diagnosis and adjusted for age at diagnosis, attained level of education, physical activity, body mass index, alcohol consumption reported at recruitment, smoking habit and intensity as cigarettes per day at recruitment, ever use of hormone for menopause at diagnosis, cancer stage at diagnosis, cancer grade, and tumour receptor status: ER, PR, HER2.
BMI body mass index, HER2 human epidermal receptor status 2, HR, Hazard Ratio; CI, Confidence Interval; DRRD, Diabetes risk reduction diet; ISD, Inflammatory score of diet; ERDP, Oestrogen-related dietary pattern.
aUsing the scores as residuals of multiple regression model including DRRD, ISD and ERDP.
bP-values for heterogeneity by introducing interaction terms in the multivariable models between the dietary pattern and the variable containing the subgroups using likelihood ratio tests.
cIn situ BC cases are not included in these analyses since they are only 14 with 1 single event (death).